ArticleDrugs in R&D2026
Analytical Characterization for Similarity Assessment Between Biosimilar SB16 and Denosumab Reference Product Using State-of-the-Art Analytical Method.
Article in Drugs in R&D, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectiveSB16 has been developed and recently approved as a biosimilar to denosumab reference product, which inhibits osteoclast formation by targeting receptor activator of nuclear factor kappa-B ligand. This study presents a comprehensive analytical characterization of SB16 denosumab biosimilar to demonstrate high similarity to the reference product (Prolia and Xgeva).
methodsAnalytical similarity was assessed using side-by-side comparisons and similarity range approaches with state-of-the-art methods. Critical quality attributes evaluated included primary structure, post-translational modifications, higher order structure, purity, glycosylation, charge heterogeneity, and biological activities. Similarity ranges were established using extensive reference product lot testing (up to 68 EU Prolia, 35 US Prolia, 29 EU Xgeva, and 17 US Xgeva lots).
resultsPeptide mapping confirmed 100% sequence coverage with identical amino acid sequences. Higher order structure analyses (circular dichroism, Fourier transform infrared, differential scanning calorimetry, hydrogen/deuterium exchange-mass spectrometry) demonstrated similar secondary and tertiary structures. Purity assessments (size exclusion-high performance liquid chromatography, Capillary electrophoresis-sodium dodecyl sulfate) showed similar monomer content and impurity profiles. N-glycan profiling revealed similar high mannose species; galactosylation differences were deemed not clinically meaningful. Charge heterogeneity (imaging capillary isoelectric focusing, cation exchange) demonstrated similar charge variant profiles. Fab-related activities (receptor activator of nuclear factor kappa-B ligand binding, receptor activator of nuclear factor kappa-B ligand neutralization, and anti-differentiation) and Fc-related activities (neonatal fragment crystallizable receptor binding, Fc-gamma receptor binding, C1q binding, antibody-dependent cell-mediated cytotoxicity, and complement-dependent cytotoxicity) showed similar results.
conclusionsSB16 demonstrated high similarity to denosumab reference product across all structural, physicochemical, and biological properties, providing robust analytical evidence supporting biosimilarity. This dataset serves as valuable reference information for biosimilar development.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.